The polymorphism of CYP2E1 Rsa I/Pst I gene and susceptibility to respiratory system cancer: a systematic review and meta-analysis of 34 studies.
The polymorphism of CYP2E1 Rsa I/Pst I gene and susceptibility to respiratory system cancer: a systematic review and meta-analysis of 34 studies.
复制标题
CYP2E1 Rsa I/Pst I 基因多态性与呼吸系统癌症易感性：34 项研究的系统评价和荟萃分析。
DOI：
10.1097/md.0000000000000178
复制
发表时间：
2014-12
期刊：
影响因子：
1.6
通讯作者：
Chen H
中科院分区：
文献类型：
--
作者：
Xu L;Yang M;Zhao T;Jin H;Xu Z;Li M;Chen H
本研究的目的是探讨细胞色素P450 2E1(细胞色素P450 2E1)Rsa I/Pst I基因多态性与呼吸系统肿瘤的关系。呼吸系统肿瘤包括肺癌、喉癌、鼻咽癌和其他呼吸系统肿瘤，是世界范围内最常见的恶性肿瘤，已有报道指出CYP2E1Rsa I/Pst I基因多态性与某些呼吸系统肿瘤有显著关系，但其他一些研究结果存在争议。计算合并优势比(OR)和95%可信区间(CI)来评估这种关联性。应用计算机检索PubMed、EMbase、Cochrane图书馆、中国国家知识基础设施、万方数据库(截至2014年7月20日)的病例对照研究，主要研究CYP2E1Rsa I/Pst I基因多态性与呼吸系统肿瘤易感性的关系。共收集到332篇文献，经2位评价者评价，其中34篇研究7028个病例和9822个对照符合纳入标准。按肿瘤部位分层，在纯合子模型(C2C2 vs C1C1：or = 1.85，95%CI = 1.20~2.85，P = 0.005)和隐性模型(C2C2 vs C1C2/C1C1：or = 1.89，95%CI = 1.23~2.89，P = 0.003)下，C2/C2多态可增加患鼻咽癌的风险。杂合子模型(C1C2 vs C1C1：OR = 0.82，95%CI = 0.74~0.91，P <； 0.001)、显性模型(C1C2/C2C2 vs C1C1：OR = 0.83，95%CI = 0.76~0.90，P <； 0.001)和等位基因对照模型(C2 vs C1：or = 0.85，95%CI = 0.73~1.00，P = 0.045)对肺癌有保护作用。在种族亚群分析方面，亚洲人群在杂合子模型(C1C2 vs C1C1：or = 0.85，95%CI = 0.78~0.94，P = 0.001)、显性模型(C1C2/C2C2 vs C1C1：OR = 0.88，95%CI = 0.81~0.95，P = 0.001)和隐性模型(C2C2 vs C1C2/C1C1：or = 1.25，95%CI = 1.01-1.53，P = 0.036)。CYP2E1Rsa I/Pst I基因多态性可能降低患呼吸系统癌症的风险。此外，在亚洲人群中也发现了显著的关联。
The purpose of this articles is to determine whether the cytochrome P450 2E1 (CYP2E1) Rsa I/Pst I gene polymorphism is correlated with respiratory system cancers. Respiratory system cancers included lung cancer, laryngeal cancer, nasopharyngeal cancer, and cancers of other respiratory organs, which are the most common malignant tumors worldwide; the significant relationship between CYP2E1 Rsa I/Pst I gene polymorphism and some respiratory system cancer have been reported, but results of some other studies are controversial. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the association. PubMed, EMBASE, Cochrane Library Databases, China National Knowledge Infrastructure, and Wanfang Database (up to July 20, 2014) were searched for all case–control studies those mainly studied the relationship between CYP2E1 Rsa I/Pst I gene polymorphism and the susceptibility of respiratory system cancer. A total of 332 articles were collected, among which 34 studies that involved 7028 cases and 9822 controls fulfilled the inclusion criteria after being assessed by 2 reviewers. When stratified by cancer site, the C2/C2 polymorphism could increase the risk of nasopharyngeal cancer under the homozygote model (C2C2 vs C1C1: OR = 1.85, 95% CI = 1.20–2.85, P = 0.005) and recessive model (C2C2 vs C1C2/C1C1: OR = 1.89, 95% CI = 1.23–2.89, P = 0.003). Protection effect was found in lung cancer in heterozygote model (C1C2 vs C1C1: OR = 0.82, 95% CI = 0.74–0.91, P < 0.001), dominant model (C1C2/C2C2 vs C1C1: OR = 0.83, 95% CI = 0.76–0.90, P < 0.001), and allele contrast model (C2 vs C1: OR = 0.85, 95% CI = 0.73–1.00, P = 0.045). With regard to ethnicity subgroup analysis, there was significant association in Asian population in heterozygote model (C1C2 vs C1C1: OR = 0.85, 95% CI = 0.78–0.94, P = 0.001), dominant model (C1C2/C2C2 vs C1C1: OR = 0.88, 95% CI = 0.81–0.95, P = 0.001), and recessive model (C2C2 vs C1C2/C1C1: OR = 1.25, 95% CI = 1.01–1.53, P = 0.036). CYP2E1 Rsa I/Pst I gene polymorphism may reduce the risk of respiratory system cancer. Furthermore, significant association was also found in Asian populations.